Stockscreener 앱 받기
54.84
2.30%
-1.29
시간 외 거래:
54.46
-0.38
-0.69%
전일 마감가:
$56.13
열려 있는:
$55.7
하루 거래량:
3.52M
Relative Volume:
1.27
시가총액:
$10.35B
수익:
$2.83B
순이익/손실:
$-1.02B
주가수익비율:
-9.9528
EPS:
-5.51
순현금흐름:
$194.14M
1주 성능:
-3.04%
1개월 성능:
+6.38%
6개월 성능:
-9.45%
1년 성능:
+22.36%
1일 변동 폭
$54.35
$56.02
1주일 범위
$54.35
$58.68
52주 변동 폭
$39.97
$72.83
이그젝트 사이 Stock (EXAS) Company Profile
명칭
Exact Sciences Corp
전화
608-284-5700
주소
5505 ENDEAVOR LANE, MADISON, WI
EXAS을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
54.84 | 10.67B | 2.83B | -1.02B | 194.14M | -5.51 |
|
TMO
Thermo Fisher Scientific Inc
|
399.93 | 152.34B | 42.90B | 6.52B | 6.72B | 17.05 |
|
DHR
Danaher Corp
|
192.06 | 135.39B | 23.82B | 3.77B | 4.90B | 5.15 |
|
IDXX
Idexx Laboratories Inc
|
525.83 | 41.54B | 3.93B | 894.97M | 837.70M | 10.82 |
|
A
Agilent Technologies Inc
|
112.76 | 31.61B | 6.63B | 1.17B | 1.19B | 4.05 |
|
IQV
Iqvia Holdings Inc
|
142.78 | 24.31B | 15.50B | 1.33B | 2.16B | 7.34 |
이그젝트 사이 Stock (EXAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-01-02 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-10-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-08-02 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-05-10 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2023-05-05 | 개시 | UBS | Neutral |
| 2023-03-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-02-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2021-11-03 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 재확인 | BTIG Research | Buy |
| 2021-07-29 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-29 | 재확인 | Oppenheimer | Outperform |
| 2021-07-29 | 재확인 | Stifel | Buy |
| 2021-06-15 | 개시 | Raymond James | Strong Buy |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Equal Weight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-29 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-04-02 | 개시 | Evercore ISI | Outperform |
| 2020-01-10 | 재개 | BTIG Research | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Dougherty & Company | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-10-17 | 재확인 | BofA/Merrill | Buy |
| 2019-10-01 | 재개 | Craig Hallum | Buy |
| 2019-09-26 | 개시 | Oppenheimer | Outperform |
| 2019-02-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-09 | 개시 | UBS | Buy |
| 2018-09-05 | 재개 | The Benchmark Company | Hold |
| 2018-08-13 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-01-29 | 개시 | Goldman | Neutral |
| 2018-01-08 | 재확인 | The Benchmark Company | Buy |
| 2017-11-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
모두보기
이그젝트 사이 주식(EXAS)의 최신 뉴스
Epigenetics Market Anticipated to Achieve 11.8% CAGR - GlobeNewswire Inc.
Exact Sciences at William Blair Conference: Vision for Cancer Eradication - Investing.com
Transcript : Exact Sciences Corporation Presents at 45th Annual William Blair Growth Stock Conference, Jun-03-2025 08 - marketscreener.com
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap - Business Wire
Exact Sciences Clears Technical Benchmark, Hitting 80-Plus RS Rating - inkl
Exact Sciences Announces Expanded Clinical Validation Of Oncodetect Test And Molecular Residual Disease Innovation Roadmap - marketscreener.com
Exact Sciences to present new positive data on Oncodetect in colorectal cancer - TipRanks
Exact Sciences (EXAS) Unveils Advanced MRD Test Data for Colorectal Cancer | EXAS Stock News - GuruFocus
Exact Sciences Announces Expanded Clinical Validation of the Onc - GuruFocus
Exact Sciences Announces Expanded Clinical Validation of the Oncodetect™ Test and Molecular Residual Disease Innovation Roadmap | EXAS Stock News - GuruFocus
Exact Sciences management to meet with Oppenheimer - TipRanks
Exact Sciences to Participate in June Investor Conference | EXAS Stock News - GuruFocus
Exact Sciences to Participate in June Investor Conference - New Castle News
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Sells 2,099 Shares of Exact Sciences Co. (NASDAQ:EXAS) - Defense World
Exact Sciences Highlights Innovations in Early Cancer Detection - GuruFocus
Exact Sciences Highlights Innovations in Early Cancer Detection and Precision Oncology at ASCO 2025 - Business Wire
WisBusiness: the Show with Kevin Boggs of Medical College of Wisconsin - WisBusiness
Exact Sciences Corporation (EXAS) Slid on Fear of Competition - Insider Monkey
Comerica Bank Lowers Position in Exact Sciences Co. (NASDAQ:EXAS) - Defense World
EXAS Q1 Earnings Call: Outperformance Driven by Commercial Execution, New Products, and Margin Expansion - Yahoo Finance
10 High PE Stocks Insiders Are Buying - Insider Monkey
Exact Sciences at Bank of America 2025 Healthcare Conference: Strategic Growth and Innovation - Investing.com
Transcript : Exact Sciences Corporation Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 10 - marketscreener.com
2 Brilliant Stocks to Buy With $200 and Hold for 5 Years - AOL.com
Exact Sciences Co. (NASDAQ:EXAS) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Exact Sciences Earns 2025 Great Place To Work® Certification™ - Business Wire
Functional Genomics Market Top PlayersExact Sciences - openPR.com
Exact Sciences Announces First-Quarter 2025 Results - ADVFN
Exact Sciences (NASDAQ:EXAS) Price Target Raised to $72.00 - Defense World
Analysts Have Made A Financial Statement On Exact Sciences Corporation's (NASDAQ:EXAS) First-Quarter Report - Yahoo
Exact Sciences Corporation (NASDAQ:EXAS) Q1 2025 Earnings Call Transcript - Insider Monkey
Decoding Exact Sciences Corp (EXAS): A Strategic SWOT Insight - GuruFocus
Exact Sciences Corp Reports Strong Start to 2025 - TipRanks
Exact Sciences (EXAS) Target Price Raised by Barclays to $75 | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Price Target Raised by RBC Capital | EXAS Stock News - GuruFocus
Exact Sciences: Q1 Earnings Snapshot - GMToday.com
Lobbying Update: $470,000 of EXACT SCIENCES lobbying was just disclosed - Nasdaq
Exact Sciences (EXAS) Reports Earnings Tomorrow: What To Expect - Barchart.com
Trupanion Posts Better-Than-Expected Results, Joins Duolingo, DexCom, Exact Sciences And Other Big Stocks Moving Higher On Friday - Benzinga
Exact Sciences (EXAS) Sees Target Price Raised by Baird | EXAS S - GuruFocus
EXAS: Evercore ISI Group Raises Price Target for Exact Sciences - GuruFocus
EXAS: Evercore ISI Group Raises Price Target for Exact Sciences | EXAS Stock News - GuruFocus
Exact Sciences (EXAS) Sees Target Price Raised by Baird | EXAS Stock News - GuruFocus
Cancer Diagnostic Firm Exact Sciences' CEO Says Strong Q1 Paves Way For 'Transformative' 2025, Lifts Annual Guidance - Benzinga
Exact Sciences (EXAS) Price Target Raised to $72 by Baird Analys - GuruFocus
RBC Raises Price Target on Exact Sciences to $54 From $52, Keeps Sector Perform Rating - marketscreener.com
Exact Sciences (EXAS) Price Target Raised to $72 by Baird Analyst | EXAS Stock News - GuruFocus
S&P 500 Futures Rise in Premarket Trading; McCormick Vtg, Exact Sciences Lead - Barron's
Exact Sciences to Participate in May Investor Conference | EXAS Stock News - GuruFocus
Barclays Elevates Price Target for Exact Sciences (EXAS) to $75 - GuruFocus
Exact Sciences to Participate in May Investor Conference - Business Wire
이그젝트 사이 (EXAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
이그젝트 사이 주식 (EXAS) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Conroy Kevin T | President and CEO |
Mar 07 '25 |
Option Exercise |
22.38 |
66,723 |
1,493,261 |
1,203,269 |
| Herriott James | SVP, General Counsel & Sec |
Feb 28 '25 |
Option Exercise |
0.00 |
4,265 |
0 |
16,339 |
| Conroy Kevin T | President and CEO |
Feb 28 '25 |
Option Exercise |
0.00 |
40,310 |
0 |
1,146,965 |
| Baranick Brian | EVP, GM, Precision Oncology |
Feb 28 '25 |
Option Exercise |
0.00 |
9,673 |
0 |
25,106 |
| ORVILLE JACOB A | EVP, GM, Screening |
Feb 28 '25 |
Option Exercise |
0.00 |
9,673 |
0 |
27,728 |
| Condella Sarah | EVP, Human Resources |
Feb 28 '25 |
Option Exercise |
0.00 |
7,738 |
0 |
84,399 |
| Condella Sarah | EVP, Human Resources |
Feb 25 '25 |
Option Exercise |
0.00 |
3,954 |
0 |
80,297 |
| Baranick Brian | EVP, GM, Precision Oncology |
Feb 25 '25 |
Option Exercise |
0.00 |
3,954 |
0 |
19,841 |
| Herriott James | SVP, General Counsel & Sec |
Feb 25 '25 |
Option Exercise |
0.00 |
1,647 |
0 |
13,738 |
| ORVILLE JACOB A | EVP, GM, Screening |
Feb 25 '25 |
Option Exercise |
0.00 |
3,954 |
0 |
22,136 |
0.46%
1.66%
자본화:
|
볼륨(24시간):